Bicycle Therapeutics to Present at the Oppenheimer 31st Annual Healthcare Conference

Rhea-AI Summary

Bicycle Therapeutics, a biotechnology company specializing in innovative therapeutics, will participate in a fireside chat at the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021, at 8:40 a.m. ET. The event will be conducted virtually and will be accessible via a live webcast on Bicycle's website. Additionally, an archived replay will be available for 90 days post-event. Bicycle is known for its proprietary Bicycles technology, with ongoing clinical trials for its lead product candidate, BT1718, and additional candidates BT5528 and BT8009.

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle ®) technology, today announced that management will participate in a fireside chat at the Oppenheimer 31^st Annual Healthcare Conference on March 16, 2021 at 8:40 a.m. ET. The conference will be held in a virtual meeting format.

A live webcast of the fireside chat will be accessible in the Investors & Media section of Bicycle’s website at www.bicycletherapeutics.com. An archived replay of the webcast will be available for 90 days following the presentation date.

About Bicycle Therapeutics

Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles^®, for diseases that are underserved by existing therapeutics. Bicycles are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycles attractive candidates for drug development. Bicycle’s lead product candidate, BT1718, a Bicycle Toxin Conjugate (BTC) that targets MT1-MMP, is being investigated in an ongoing Phase I/IIa clinical trial in collaboration with the Centre for Drug Development of Cancer Research UK. Bicycle is also evaluating BT5528, a second-generation BTC targeting EphA2, in a Company-sponsored Phase I/II study. BT8009 is a BTC targeting Nectin-4, a well-validated tumor antigen, and is also currently being evaluated a Company-sponsored Phase I/II trial. Bicycle is headquartered in Cambridge, UK with many key functions and members of its leadership team located in Lexington, MA. For more information, visit bicycletherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210311005352/en/

FAQ

What is the date and time of Bicycle Therapeutics' participation in the Oppenheimer 31st Annual Healthcare Conference?

Bicycle Therapeutics will participate on March 16, 2021, at 8:40 a.m. ET.

How can I watch the Bicycle Therapeutics fireside chat?

The fireside chat can be watched live on Bicycle's website under the Investors & Media section.

Will there be a replay available for the Bicycle Therapeutics webcast?

Yes, an archived replay of the webcast will be available for 90 days after the presentation.

What are the key product candidates being developed by Bicycle Therapeutics?

Bicycle's key candidates include BT1718, BT5528, and BT8009, which target various tumor antigens.

What technology does Bicycle Therapeutics focus on?

Bicycle Therapeutics focuses on developing therapeutics based on its proprietary bicyclic peptide technology.